Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.56 |
| ▸ | CCNK | O75909 | 2/20 | 0.43 |
| ▸ | CCND3 | P30281 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 5/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 4/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17580874 | 0.77 | BTK (0.72) | BTKKDRLCKMAPK14F10 | |
| SCHEMBL2464982 | 0.75 | BTK (0.49) | BTKKDRLCKMAPK14F10 | |
| SCHEMBL13893944 | 0.74 | BTK (0.53) | BTK | |
| SCHEMBL2467008 | 0.74 | BTK (0.54) | BTKSRC | |
| SCHEMBL19981889 | 0.72 | BTK (0.45) | BTKCCNKCCND3CDK9CDK6 | |
| SCHEMBL1322473 | 0.72 | BTK (1.00) | BTK | |
| SCHEMBL2492037 | 0.72 | BTK (0.59) | BTKSRC | |
| SCHEMBL9984944 | 0.72 | BTK (0.44) | BTKSRC | |
| SCHEMBL2490514 | 0.72 | BTK (0.55) | BTKFLT3 | |
| SCHEMBL2488701 | 0.71 | BTK (0.70) | BTKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598174-B2 | Pyridazinones, method of making, and method of use thereof | GENETECH, INC. (US) | 2013-12-03 | — | — | US | claimed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | claimed |
| EP-2365970-A1 | Pyridazinones and their use as btk inhibitors | CGI Pharmaceuticals, Inc. (US) | 2011-09-21 | — | — | EP | claimed |
| WO-2010056875-A1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| EP-2365970-B1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-8598174-B2 | Pyridazinones, method of making, and method of use thereof | GENETECH, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2365970-A1 | Pyridazinones and their use as btk inhibitors | CGI Pharmaceuticals, Inc. (US) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010056875-A1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, LCK | BTK 1/4885CCNK 638/4885CCND3 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.